DEFA14A: Repare Therapeutics Acquired by XenoTherapeutics

Repare Therapeutics Inc. announced a definitive agreement to be acquired by XenoTherapeutics, Inc., with shareholders receiving cash and contingent value rights.

Summary

• Repare Therapeutics Inc. entered into a definitive arrangement agreement with XenoTherapeutics, Inc. and Xeno Acquisition Corp. (jointly, Xeno) for Xeno to acquire all issued and outstanding common shares of Repare.
• The acquisition is anticipated to become effective during the first quarter of 2026, subject to customary closing conditions, including shareholder and final court approval.
• Repare shareholders will receive an estimated cash payment of US$1.82 per Common Share at closing, which will be determined based on Repare's cash balance after deducting transaction costs and outstanding liabilities.
• Each Repare shareholder will also receive one non-transferable contingent value right (CVR) per Common Share, entitling them to a pro-rata share of certain future cash payments.
• CVR payments include 100% of certain additional receivables within 90 days post-closing, a percentage (90% to 75%) of net proceeds from existing partnerships (Bristol-Myers Squibb, Debiopharm, DCx Biotherapeutics) over 10 years, and 100% or 50% of net proceeds from future licensing or disposition of product candidates and intellectual property (RP-1664, RP-3500, Polq, RP-3467, other programs) within 10 years.
• The Board of Directors, following a thorough strategic review and recommendation from its strategic deal committee, unanimously determined the Arrangement is fair and in the best interests of the Company and its stakeholders, recommending shareholders vote in favor.
• This Arrangement follows Repare's January 2025 announcement of resource re-alignment, clinical portfolio re-prioritization, and planned cost/headcount reductions, including an approximately 75% workforce reduction in March 2025 to extend its cash runway.
• The Company considered various strategic alternatives, including voluntary liquidation, but concluded the Arrangement was the most advantageous transaction for its stakeholders.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the context of the acquisition following significant workforce reductions and consideration of liquidation, indicating a distressed sale. While shareholders receive cash and CVRs, the underlying circumstances reflect severe operational and financial challenges that led to the sale.

Positives

• Shareholders will receive an estimated cash payment of US$1.82 per Common Share at closing.
• Shareholders will receive Contingent Value Rights (CVRs) offering potential future payments from existing partnerships and future licensing/disposition of product candidates, allowing for continued participation in milestones and royalties.
• The Board of Directors unanimously recommended the Arrangement, deeming it fair from a financial perspective and in the best interests of the Company and its stakeholders.
• The exercise and termination period for all employee Options and RSUs will be extended to the closing date, with full vesting acceleration at closing.

Negatives

• The acquisition follows significant operational challenges, including a re-alignment of resources, re-prioritization of the clinical portfolio, and an approximately 75% workforce reduction in March 2025.
• The company considered voluntary liquidation as an alternative, indicating severe financial distress prior to the acquisition.
• The CVRs are non-transferable and not registered with the SEC, limiting liquidity and transparency for holders.
• The final cash amount per share is an estimate and will be ultimately determined based on the company's cash balance at closing, after deducting transaction costs and liabilities, which could result in a lower payment.
• Options with an exercise price greater than or equal to the Cash Amount will be cancelled without payment, unless exercised prior to closing at the holder's own risk.

Risks

• The Arrangement remains subject to customary closing conditions, including receipt of shareholder approval at a special meeting and final court approval.
• The Company believes it was classified as a Passive Foreign Investment Company (PFIC) for the taxable year ending December 31, 2024, and certain prior years, and expects to be classified as a PFIC for the current taxable year, which could lead to adverse U.S. federal income tax consequences for U.S. Holders.
• The U.S. federal income tax treatment of the receipt of CVRs and payments made with respect to them is uncertain, with potential for 'closed transaction' or 'open transaction' treatment, and the application of imputed interest under Section 483 of the Code.
• Canadian federal income tax consequences for the receipt, holding, and disposition of CVRs are not entirely clear and depend on the specific circumstances and interpretation of complex rules.
• CVRs will not be qualified investments for certain Canadian registered plans (e.g., RRSPs, RRIFs, TFSAs), potentially subjecting the trust or holder to penalty taxes.
• If the distribution is treated as an ordinary distribution rather than a return of capital, U.S. Holders may face significant adverse tax consequences, particularly if the Company is classified as a PFIC.

Future Outlook

Following the consummation of the Arrangement, Repare Therapeutics' Common Shares will be wholly owned by Xeno, delisted from Nasdaq, and deregistered under the U.S. Exchange Act. The company will cease to have public reporting obligations in the U.S. and Quebec.

Management Comments

• "The Board of Directors, upon recommendation of the strategic deal committee, determined that it was in the best interest of the Company to enter into the Arrangement Agreement with Xeno for the sale of all of its Common Shares."
• "The Board of Directors unanimously determined that: (i) the Arrangement is fair, from a financial point of view, to the securityholders of the Company, and (ii) the Arrangement is in the best interests of the Company and its stakeholders."
• "Accordingly, the Board of Directors unanimously recommended that the shareholders vote in favor of the Arrangement Agreement and recommended that the shareholders vote in favor of the Arrangement at the Meeting."

Industry Context

The acquisition of a biotechnology company by a non-profit biotechnology company, following significant restructuring and workforce reductions, suggests a challenging market for smaller biotech firms or a strategic pivot for the acquiring entity. The Contingent Value Right (CVR) structure is a common mechanism in biotech acquisitions to bridge valuation gaps and share future upside from pipeline assets, especially when the target company has early-stage or unproven assets.

Stakeholder Impact

• Shareholders will receive an estimated cash payment and CVRs, providing a return of capital and potential future upside from existing partnerships and pipeline assets. However, the CVRs are illiquid and subject to contingencies, and the overall transaction follows a period of significant company distress.
• Employees who remain employed until closing will have their Options and RSUs fully vested and their exercise/termination period extended. However, the prior 75% workforce reduction indicates significant job losses and uncertainty for the remaining workforce.

Next Steps

• Shareholder approval at a special meeting, expected on or about January 16, 2026.
• Final court approval of the Arrangement.
• Closing of the Arrangement, anticipated in the first quarter of 2026.
• Delisting of Common Shares from Nasdaq.
• Deregistration of Common Shares under the U.S. Exchange Act.
• Application to cease being a reporting issuer in Quebec.
• Company continues to endeavor to license or dispose of product candidates and/or intellectual property related to its RP-3467 and Polq program, RP-1664 program, RP-3500 (Camonsertib) program, and/or any other product candidates or research programs prior to closing.

Key Dates

Recommendation

The company is being acquired after a period of significant financial distress, including a 75% workforce reduction and consideration of voluntary liquidation. While shareholders receive an estimated cash payment and contingent value rights (CVRs), the CVRs are illiquid, non-transferable, and contingent on future events, making their value speculative. The acquisition represents an exit for existing shareholders under challenging circumstances, suggesting that the company's standalone prospects were poor. Investors should take the cash and CVRs and exit, as the company will cease to exist as a publicly traded entity, eliminating future market liquidity for the shares.

Keywords

Repare Therapeutics, XenoTherapeutics, acquisition, merger, biotechnology, SEC filing, DEFA14A, proxy statement, contingent value rights, CVR, shareholder approval, delisting, Nasdaq, PFIC, tax considerations, workforce reduction, clinical portfolio, strategic review